Finding new treatments for glioblastoma using DNA aptamers
Official title: In vivo SELEX strategies to identify potent aptamer-drug conjugates for glioblastoma
Funded at Mayo Clinic Rochester · NIH-10910176 · Data updated 2026-11-12
This study is exploring new ways to treat glioblastoma, a tough type of brain cancer, by using special DNA pieces that can help deliver medicine directly to the tumor, making treatments more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 21, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $386,233 |
| NIH project number | 5R61NS128071-02 |
| Project ID | NIH-10910176 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have been diagnosed with glioblastoma.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research focuses on developing innovative therapies for glioblastoma, a challenging brain cancer. The approach involves using DNA aptamers, which are small pieces of DNA that can bind to specific targets in the tumor, to create drug conjugates that can effectively cross the blood-brain barrier. By employing advanced techniques like SELEX, researchers aim to identify aptamers that can deliver drugs directly to the tumor cells, potentially improving treatment outcomes. This study seeks to address the limitations of current therapies by enhancing drug delivery to the brain.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in using aptamers for targeted drug delivery, indicating that this approach could be a significant advancement in glioblastoma treatment.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Sarkaria, Jann N. — Mayo Clinic Rochester
- Study coordinator: Sarkaria, Jann N.
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.